Edition:
India

Achieve Life Sciences Inc (ACHV.OQ)

ACHV.OQ on NASDAQ Stock Exchange Capital Market

1.94USD
23 Aug 2019
Change (% chg)

$-0.00 (-0.00%)
Prev Close
$1.94
Open
$2.01
Day's High
$2.13
Day's Low
$1.90
Volume
46,646
Avg. Vol
43,671
52-wk High
$5.24
52-wk Low
$1.07

Latest Key Developments (Source: Significant Developments)

Achieve Life Sciences Announces Statistically Significant Improvement In Quit Rates In Phase 2B Trial
Tuesday, 11 Jun 2019 

June 11 (Reuters) - Achieve Life Sciences Inc ::ACHIEVE LIFE SCIENCES ANNOUNCES STATISTICALLY SIGNIFICANT IMPROVEMENT IN QUIT RATES FOR SIMPLIFIED CYTISINICLINE DOSING SCHEDULE IN PHASE 2B ORCA-1 DOSE-SELECTION TRIAL.ACHIEVE LIFE SCIENCES INC - CYTISINICLINE WAS WELL-TOLERATED WITH NO SERIOUS ADVERSE EVENTS REPORTED.ACHIEVE LIFE SCIENCES INC - THREE OF FOUR CYTISINICLINE TREATMENT ARMS DEMONSTRATED A STATISTICALLY SIGNIFICANT IMPROVEMENT.ACHIEVE LIFE SCIENCES INC - EXPECTS TO CONDUCT FURTHER ANALYSES OF ORCA-1 TRIAL AND SUBMIT DATA FOR PRESENTATION AT A FUTURE MEDICAL MEETING.ACHIEVE LIFE SCIENCES INC - ALL FOUR CYTISINICLINE ARMS DEMONSTRATED STATISTICALLY SIGNIFICANT (P < 0.05) REDUCTIONS IN EXPIRED CO.ACHIEVE LIFE SCIENCES INC - PLANS TO DISCUSS TRIAL'S OUTCOME WITH FDA AND FINALIZE PHASE 3 PROTOCOL DETAILS IN SECOND-HALF OF 2019.ACHIEVE LIFE SCIENCES INC - 3.0 MG, 3 TIMES DAILY SELECTED AS DOSE FOR FUTURE CLINICAL DEVELOPMENT.ACHIEVE LIFE SCIENCES INC - FOURTH CYTISINICLINE TREATMENT ARM TRENDED TO SIGNIFICANCE (P= 0.052).  Full Article

Achieve Life Sciences Inc Posts Q4 Loss Per Share of $0.55
Friday, 15 Mar 2019 

March 14 (Reuters) - Achieve Life Sciences Inc ::ACHIEVE LIFE SCIENCES INC - Q4 LOSS PER SHARE $0.55.  Full Article

Achieve Reports Financial Results For Year-End 2018 And Provides Cytisinicline Clinical Development Update
Friday, 15 Mar 2019 

March 14 (Reuters) - Achieve Life Sciences Inc ::ACHIEVE REPORTS FINANCIAL RESULTS FOR YEAR-END 2018 AND PROVIDES CYTISINICLINE CLINICAL DEVELOPMENT UPDATE.ACHIEVE LIFE SCIENCES INC - AS OF DECEMBER 31, 2018, CASH, CASH EQUIVALENTS, SHORT-TERM INVESTMENTS AND RESTRICTED CASH WERE $14.7 MILLION.ACHIEVE LIFE SCIENCES INC - QTRLY LOSS PER SHARE $0.55.  Full Article

Achieve Announces Update On Cytisinicline Clinical Development Program
Tuesday, 18 Dec 2018 

Dec 18 (Reuters) - Achieve Life Sciences Inc ::ACHIEVE ANNOUNCES UPDATE ON CYTISINICLINE CLINICAL DEVELOPMENT PROGRAM.ACHIEVE LIFE SCIENCES INC - FDA CONFIRMED THAT THEY ARE IN AGREEMENT WITH ACHIEVE'S INITIAL PEDIATRIC STUDY PLAN.ACHIEVE LIFE SCIENCES - AGREED PEDIATRIC STUDY PLAN WILL BE INCLUDED AS PART OF ACHIEVE'S FUTURE APPLICATION FOR MARKETING APPROVAL OF CYTISINICLINE.ACHIEVE LIFE SCIENCES - FDA IN AGREEMENT WITH INITIAL PLAN, SPECIFICALLY, PROVIDING FULL WAIVER FOR EVALUATING CYTISINICLINE IN PEDIATRIC POPULATION.  Full Article

Achieve Announces Results Of Clinical Study Demonstrating Similar Bioavailability For A New Cytisine Formulation In Fed And Fasted Subjects
Thursday, 27 Sep 2018 

Sept 27 (Reuters) - Achieve Life Sciences Inc ::ACHIEVE ANNOUNCES RESULTS OF CLINICAL STUDY DEMONSTRATING SIMILAR BIOAVAILABILITY FOR A NEW CYTISINE FORMULATION IN FED AND FASTED SUBJECTS.ACHIEVE LIFE SCIENCES INC - 3 MG DOSE OF NEW FORMULATION OF CYTISINE WAS VERY WELL TOLERATED.ACHIEVE LIFE SCIENCES INC - STUDY RESULTS DEMONSTRATED BIOEQUIVALENCE WHEN CYTISINE WAS ADMINISTERED WITH OR WITHOUT FOOD.  Full Article

Achieve Life Sciences Inc QTRLY Loss Per Share $1.82
Thursday, 9 Aug 2018 

Achieve Life Sciences Inc ::ACHIEVE REPORTS FINANCIAL RESULTS FOR SECOND QUARTER 2018 AND PROVIDES CYTISINE CLINICAL DEVELOPMENT UPDATE.ACHIEVE LIFE SCIENCES INC QTRLY LOSS PER SHARE $1.82.ACHIEVE LIFE SCIENCES - AS OF JUNE 30, CO'S CASH, CASH EQUIVALENTS, SHORT-TERM INVESTMENTS AND RESTRICTED CASH WAS $15.3 MILLION.  Full Article

Achieve Life Sciences Announces Advancement Of Cytisine Development Program Following Meeting With The FDA
Wednesday, 11 Jul 2018 

July 11 (Reuters) - Achieve Life Sciences Inc ::ACHIEVE LIFE SCIENCES ANNOUNCES ADVANCEMENT OF CYTISINE DEVELOPMENT PROGRAM FOLLOWING MEETING WITH THE FDA.ACHIEVE LIFE SCIENCES INC - ACHIEVE PLANS TO INITIATE PHASE 2B TRIAL IN Q4 OF 2018.ACHIEVE LIFE SCIENCES - FOLLOWING RESULTS FROM PHASE 2B OPTIMIZATION TRIAL, CO PLANS TO INITIATE PHASE 3 PROGRAM IN 2019.ACHIEVE LIFE SCIENCES - BASED ON FDA'S RECOMMENDATIONS, PLANS TO CONDUCT PHASE 2B OPTIMIZATION TRIAL IN ABOUT 250 SMOKERS IN U.S..  Full Article

Achieve Announces Patent Granted On Novel Formulation Of Cytisine
Monday, 7 May 2018 

May 7 (Reuters) - Achieve Life Sciences Inc ::ACHIEVE ANNOUNCES PATENT GRANTED ON NOVEL FORMULATION OF CYTISINE.  Full Article

Achieve qtrly loss per share $0.90‍​
Friday, 10 Nov 2017 

Nov 9 (Reuters) - Achieve Life Sciences Inc ::Achieve reports financial results for third quarter 2017.Achieve Life Sciences Inc qtrly loss per share $0.90‍​.  Full Article

Achieve Life Sciences entered into exclusive supply agreement with Sopharma AD
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - Sopharma Ad <3JR.BB>:Achieve Life Sciences -‍ co entered into exclusive supply agreement with Sopharma AD for manufacture of Cytisine API and finished tablets​.Achieve Life Sciences Inc - ‍exclusive license agreement provides supply of Cytisine to co for up to 20 years​.Achieve Life Sciences Inc - ‍sopharma agrees to produce CGMP-grade Cytisine for achieve's use in development and commercialization of Cytisine​.  Full Article